Taysha Gene Therapies/$TSHA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Taysha Gene Therapies

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Ticker

$TSHA
Primary listing

Industry

Biotechnology

Employees

73

ISIN

US8776191061

TSHA Metrics

BasicAdvanced
$556M
-
-$0.33
1.02
-

What the Analysts think about TSHA

Analyst ratings (Buy, Hold, Sell) for Taysha Gene Therapies stock.

Bulls say / Bears say

Taysha's lead candidate, TSHA-102, has shown promising safety and efficacy results in early-stage clinical trials for Rett syndrome, with the Independent Data Monitoring Committee approving dose escalation ahead of schedule, potentially expediting its development timeline. (Investing.com)
The company has strengthened its financial position by raising $76.8 million through a public follow-on offering, extending its cash runway into the fourth quarter of 2026, providing ample resources to advance its clinical programs. (Investing.com)
Analysts have a consensus 'Strong Buy' rating for Taysha Gene Therapies, with an average price target of $8.20, indicating a potential upside of approximately 238.84% from the current stock price. (StockAnalysis.com)
Despite early promising results, TSHA-102 has been tested in a limited number of patients, making it challenging to draw definitive conclusions about its efficacy and safety across a broader population, which may impact investor confidence. (Investing.com)
The regulatory approval process for TSHA-102 faces potential hurdles, including the FDA's preference for randomized controlled trials over single-arm studies with natural history comparisons, which could delay approval timelines. (Investing.com)
A recent analysis initiated coverage on Taysha with a 'Sell' rating, citing high clinical risk and a potentially narrow market opportunity for its lead Rett syndrome program, suggesting that the current valuation may not justify the significant risks involved. (Seeking Alpha)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.

TSHA Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

TSHA Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $TSHA

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs